牌照 · 2025-12-05

SFC Type 12 License for OTC Derivative Trading Services: Practical Application Insights

The Securities and Futures Commission (SFC) introduced the Type 12 regulated activity licence in December 2024, specifically for over-the-counter (OTC) derivative trading services. This new licence category responds directly to a gap in Hong Kong’s regulatory framework, where firms facilitating OTC derivative transactions—such as bespoke swaps, forwards, and structured products—operated without a dedicated licensing regime. The 2025-2026 compliance cycle marks the first full reporting period under this regime, and the SFC has signalled active enforcement. Firms that previously relied on exemptions under the Securities and Futures Ordinance (Cap. 571) or conducted OTC derivative business through unlicensed affiliates now face a hard deadline to apply. The SFC’s March 2025 circular on “Regulatory Expectations for Licensed Corporations Engaging in OTC Derivative Activities” (SFC, 2025) confirmed that the transitional period for existing operators ends on 30 June 2026. Any firm still offering OTC derivative trading services without a Type 12 licence after that date risks criminal liability and potential debarment from the Hong Kong market.

What Constitutes OTC Derivative Trading Services Under Type 12

The legislation defines OTC derivative trading services narrowly but with important scope. Section 2 of Schedule 5 to the Securities and Futures Ordinance (Cap. 571) was amended by the Securities and Futures (Amendment) Ordinance 2024 to include “dealing in OTC derivative products” as a regulated activity. The SFC’s “Guidelines on the Regulation of OTC Derivative Trading” (SFC, December 2024) clarify that the activity covers three distinct functions: soliciting or inducing orders for OTC derivative products, executing transactions in OTC derivative products, and arranging for another person to execute such transactions.

Products Captured Under the Licence

The Type 12 licence applies to a defined list of OTC derivative products. The SFC guidelines specify that the regime covers interest rate swaps, currency swaps, credit default swaps, equity swaps, commodity derivatives, and structured products that embed derivative components—provided they are not exchange-traded. The critical distinction is the “OTC” nature: any derivative product not traded on a recognised exchange (as defined under section 1 of Part 1 of Schedule 1 to Cap. 571) falls within scope. The Hong Kong Exchange and Clearing Limited (HKEX) confirmed in its 2024 annual report that 68% of all derivative transactions reported to the HKTR (Hong Kong Trade Repository) in 2023 were OTC, representing a notional principal amount of HKD 12.7 trillion (HKEX, 2024). This volume underscores the market significance of the new licensing requirement.

Activities Excluded from Licensing

The SFC has carved out specific exemptions that practitioners must understand. A firm that only provides clearing or settlement services for OTC derivatives through a central counterparty (CCP) recognised by the Hong Kong Monetary Authority (HKMA) does not need a Type 12 licence. Similarly, a licensed corporation that already holds a Type 1 (dealing in securities) or Type 2 (dealing in futures contracts) licence may continue to execute OTC derivatives that fall within the definition of “securities” or “futures contracts” under Cap. 571—but only if those products are listed or traded on a recognised exchange. The SFC’s 2025 FAQ on the Type 12 regime (SFC, 2025) provides a worked example: a swap referencing an index that is not a recognised futures contract requires a Type 12 licence, even if the firm holds a Type 1 licence.

The Application Process: Step-by-Step Requirements

Firms seeking a Type 12 licence must follow a structured application process that mirrors other regulated activity licences but with additional documentary burdens. The SFC’s “Application Form for a Licence to Carry on a Regulated Activity” (Form 1) was updated in January 2025 to include a new Part 12A specifically for Type 12 applicants. The SFC’s target processing time for complete applications is 12 weeks from the date of acknowledgement, though complex applications may take longer.

Step 1: Determine Eligibility and Fit

The first step is a self-assessment against the SFC’s fit and proper criteria. The SFC will examine the corporate structure, the track record of the responsible officers (ROs), and the firm’s financial resources. The minimum paid-up capital for a Type 12 licence is HKD 5 million, with a liquid capital requirement of HKD 3 million, as stated in the Securities and Futures (Financial Resources) Rules (Cap. 571N). The SFC also requires at least two ROs who have at least five years of relevant industry experience in OTC derivatives. The SFC’s “Guidelines on the Competence of Responsible Officers” (SFC, 2024) specify that relevant experience includes structuring, trading, or risk management of OTC derivatives at a licensed institution.

Step 2: Prepare the Business and Operations Plan

The application must include a detailed business plan covering the types of OTC derivative products the firm intends to deal in, the target counterparties, and the risk management framework. The SFC’s 2025 circular on “Business Plans for Type 12 Applicants” (SFC, 2025) requires applicants to demonstrate how they will comply with the new “OTC Derivative Trading Record-Keeping Rules” (Cap. 571ZJ), which mandate that all transaction records be maintained for at least seven years. The plan must also address how the firm will report trades to the HKTR within the timelines prescribed by the Securities and Futures (OTC Derivative Transactions—Reporting and Record Keeping) Rules (Cap. 571ZI). For trades executed on or after 1 January 2025, the reporting deadline is T+1 for standardised derivatives and T+3 for bespoke products.

Step 3: Appoint Responsible Officers and Submit

Before submission, the firm must appoint at least two ROs who are individually licensed under the Type 12 licence. The SFC will interview each proposed RO to assess their competence and character. The application fee is HKD 4,740, as stated in the Securities and Futures (Fees) Rules (Cap. 571S). The SFC recommends submitting the application at least six months before the intended commencement of business to allow for processing and any follow-up queries.

Practical Compliance Considerations for Licensed Corporations

Once licensed, Type 12 firms face ongoing compliance obligations that mirror other regulated activities but include specific requirements unique to OTC derivatives. The SFC’s “Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission” (the Code of Conduct) applies in full, with additional paragraphs inserted in January 2025 to address OTC derivative trading.

Counterparty Due Diligence and Suitability

The Code of Conduct requires Type 12 licensees to conduct enhanced due diligence on counterparties before executing any OTC derivative transaction. Paragraph 5.7 of the Code of Conduct (as amended in 2025) requires that the licensee assess whether the counterparty is a “professional investor” as defined in section 1 of Part 1 of Schedule 1 to Cap. 571. For retail clients, the SFC has effectively prohibited Type 12 firms from dealing in OTC derivatives unless the product is listed on a recognised exchange—a de facto ban on retail OTC derivatives trading. The SFC’s “Suitability Obligations for OTC Derivative Transactions” (SFC, 2025) clarify that for corporate counterparties, the licensee must obtain and document the counterparty’s internal approval for the transaction, including a board resolution where the notional amount exceeds HKD 10 million.

Risk Management and Margin Requirements

Type 12 firms must maintain a robust risk management framework that covers market risk, credit risk, and operational risk specific to OTC derivatives. The Securities and Futures (Margin Requirements for Non-Centrally Cleared OTC Derivative Transactions) Rules (Cap. 571ZJ) apply to Type 12 licensees that act as financial counterparties. These rules require the exchange of variation margin on a daily basis and initial margin for transactions with a notional amount exceeding HKD 500 million. The HKMA’s “Supervisory Policy Manual on OTC Derivative Margin Requirements” (HKMA, 2025) provides additional guidance for firms that are also regulated by the HKMA, such as authorised institutions.

Record-Keeping and Reporting Obligations

The record-keeping requirements for Type 12 firms are more extensive than for other licence types. The Securities and Futures (OTC Derivative Transactions—Record Keeping) Rules (Cap. 571ZJ) require that each transaction record include the legal entity identifier (LEI) of both counterparties, the unique trade identifier (UTI), the product type, the notional amount, the maturity date, and the valuation methodology. The SFC’s “Guidelines on Trade Reporting for OTC Derivatives” (SFC, 2025) specify that reports must be submitted to the HKTR using the ISO 20022 XML format. Failure to report within the prescribed timelines attracts a maximum fine of HKD 500,000 and imprisonment for two years under section 394 of Cap. 571.

The SFC has signalled that Type 12 enforcement will be a priority for 2026. In its “Enforcement Report 2024-2025” (SFC, 2025), the SFC noted that it commenced investigations into 12 firms for suspected unlicensed OTC derivative activities during the transitional period. The SFC’s enforcement division has publicly stated that it will pursue both the firm and its individual ROs for breaches.

Recent Enforcement Actions

In January 2025, the SFC reprimanded and fined a licensed corporation HKD 4 million for failing to maintain adequate records of its OTC derivative transactions (SFC Press Release, 15 January 2025). The SFC found that the firm had not documented the suitability assessments for three corporate counterparties and had not retained trade confirmations for transactions executed between 2022 and 2024. The SFC’s statement emphasised that the firm’s conduct would have constituted a breach of the Code of Conduct even if the transactions had been executed after the Type 12 licence came into effect.

Impact on Cross-Border Operations

Firms that operate across multiple jurisdictions face particular challenges under the Type 12 regime. The SFC has confirmed that a Type 12 licence is required for any firm that “holds itself out” as carrying on a business in OTC derivative trading in Hong Kong, regardless of where the counterparty is located. The “Guidelines on the Territorial Scope of the Type 12 Licence” (SFC, 2025) clarify that a firm based in Singapore that solicits business from Hong Kong-based counterparties must obtain a Type 12 licence, unless it qualifies for the “reverse solicitation” exemption. The SFC has adopted a strict interpretation: any marketing material, website, or communication directed at Hong Kong residents triggers the licensing requirement.

Actionable Takeaways

  1. File your Type 12 application by 31 December 2025 to ensure the SFC processes it before the 30 June 2026 deadline; late applications risk a gap in licensing coverage.
  2. Review all existing OTC derivative transaction records for compliance with the new record-keeping rules under Cap. 571ZJ, and retain all documentation for at least seven years.
  3. Assess whether your current counterparty base includes retail clients; if so, cease all OTC derivative dealings with them immediately unless the product is exchange-traded.
  4. Ensure your firm’s ROs have at least five years of documented OTC derivative experience, and prepare them for the SFC’s competency interview.
  5. Audit your marketing and solicitation channels to confirm that no communication directed at Hong Kong residents triggers the reverse solicitation exemption’s limits.

本文不構成法律建議。涉及個人案件請諮詢持牌律師。